TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

TG Therapeutics, Inc.NASDAQ: TGTX

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q3 FY2026 depreciation & amortization of $73K rose 17.7% year over year, behind the +32.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 24.0% from the prior quarter. Over 3 fiscal years it compounded at -22.0% a year.

Context

  • Depreciation & amortization amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.7% toward the trailing-twelve-month pace of +32.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$73K-24.0% QoQ
Last fiscal yearDec 2025
$244K-12.9% YoY
LTMSep 2026
$316K+32.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%——
1 year-12.9%——
3-year CAGR-22.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
244K USD
Year-over-year change
-12.9%
4-year CAGR
-16.2%

Depreciation & Amortization vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +32.2% is the 3rd highest of 7, against a peer median of +1.6%.
  • Depreciation & amortization amounts to 0.0% of revenue for TGTX, versus a peer median of 9.7%.
TGTX Competitors
Depreciation & Amortization for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$44M USD—-41.9%1.1%
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M USD-7.1%-22.5%4.4%
IPHAInnate Pharma S.A.FY2025€5.09M EUR+155.3%-51.8%182.7%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$1.84M USD-31.3%-31.1%2.3%
ADAGAdagene Inc.LTM Jun 2024$515.94K USD—-25.9%63.2%
TGTXTG Therapeutics, Inc.LTM Sep 2026$316K USD+32.2%-22.0%0.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$112K USD+33.3%-34.1%—
Peer median (excluding TGTX) —+1.6%-28.5%9.7%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(348.1M)(198.34M)12.67M23.38M447.18M
Depreciation & Amortization494K515K423K280K244K
Deferred Income Tax517K000(348M)
Stock-Based Compensation61.27M19.19M37.93M42.54M64.67M
Change in Working Capital(12.22M)(1.65M)(84.66M)(109.3M)(194.54M)
Accounts Receivables(1.39M)1.39M(51.09M)(78.09M)(176.44M)
Inventory(15.99M)0(36.94M)(66.85M)(33.45M)
Accounts Payables15.99M(11.01M)192K055.88M
Other Working Capital(10.83M)7.97M3.18M35.65M(40.52M)
Other Non-Cash Items2.4M4.11M2.22M2.58M5.67M
Operating Cash Flow(295.63M)(176.17M)(31.41M)(40.52M)(24.77M)
Capital Expenditures(401K)(14K)0(45K)(214K)
Acquisitions (Net)(69K)20M000
Purchases of Investments(55.53M)(107.27M)(146.88M)(311.89M)(223.49M)
Sales of Investments55.6M87.28M96.23M310.9M237.5M
Other Investing Activities69K(20M)000
Investing Cash Flow(332K)(20.01M)(50.65M)(1.04M)13.8M
Debt Repayment40M(975K)25M137.26M0
Common Stock Issued2.22M584K46.3M01.51M
Common Stock Repurchased000(8.76M)(91.24M)
Dividends Paid00000
Other Financing Activities(800K)01.41M25K0
Financing Cash Flow41.42M(391K)72.71M128.53M(89.73M)
Effect of Forex Changes00000
Net Change in Cash(254.55M)(196.57M)(9.36M)86.97M(100.7M)
Free Cash Flow(296.04M)(176.18M)(31.41M)(40.56M)(24.99M)

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.